VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

VEE virus recombinant vector vaccine RAd/VEEV#3 encoding TC-83
Vaccine Information
  • Vaccine Name: VEE virus recombinant vector vaccine RAd/VEEV#3 encoding TC-83
  • Target Pathogen: VEE Virus
  • Target Disease: Venezuelan equine encephalitis
  • Vaccine Ontology ID: VO_0004424
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Mouse
  • Antigen: E3-E2-6K from VEEV TC-83 with two mutations in the major neutralisation site of E2 and an additional mutation at the N-terminus of E2 (Phillpotts et al., 2005)
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Mouse Response

  • Vaccine Immune Response Type: VO_0000286
  • Immune Response: Intranasal immunisation of mice with this recombinant virus produced a vigorous antibody response, with local IgA also detectable in respiratory secretions accompanied by highly significant protection against airborne VEEV challenge (Phillpotts et al., 2005).
  • Efficacy: This vaccine provided protection against low and intermediate dose challenge (73 LD50 and 640 LD50, respectively); 5 out of 6 mice survived low dose challenge and 3 out of 5 mice survived intermediate dose challenge (Phillpotts et al., 2005).
References
Phillpotts et al., 2005: Phillpotts RJ, O'brien L, Appleton RE, Carr S, Bennett A. Intranasal immunisation with defective adenovirus serotype 5 expressing the Venezuelan equine encephalitis virus E2 glycoprotein protects against airborne challenge with virulent virus. Vaccine. 2005 Feb 18; 23(13); 1615-23. [PubMed: 15694514].